Suppr超能文献

滑液中的凝血蛋白与凝血酶生成:一种血管外凝血模型

Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation.

作者信息

Chang P, Aronson D L, Borenstein D G, Kessler C M

机构信息

Division of Hematology/Oncology, George Washington University Medical Center, Washington, DC, USA.

出版信息

Am J Hematol. 1995 Oct;50(2):79-83. doi: 10.1002/ajh.2830500202.

Abstract

The coagulant content and thrombin generating potential of synovial fluid from patients with osteoarthritis were studied as a model of extravascular coagulation. The concentrations of individual coagulant proteins were partially correlated with their molecular weight. The levels of the very large coagulants factor V, factor VIII and von Willebrand factor antigen (vWF:ag) are less than 1% of the activities found in a normal pooled reference plasma while smaller coagulants including factors IX, XI and prothrombin range between 9 and 30%. The protease inhibitors antithrombin-III (AT-III) and Alpha-2 macroglobulin in synovial fluid were present at levels of 74% and 13% of plasma, higher than expected based on their molecular weights. Prothrombin was more rapidly activated by tissue thromboplastin than by aPTT reagent. The thrombin activity formed in synovial fluid decreased more rapidly than that formed in dilute plasma. The addition of recombinant factor VIII or bovine factor V to synovial fluid accelerated the thrombin production by APTT but not by tissue thromboplastin. Indicating that the low levels of factor VIII and factor V did limit the rate of thrombin production. The addition of specific antibodies to factor VIII or factor V strongly inhibited thrombin production by aPTT. These data confirm a roughly inverse relationship between the concentrations of coagulation proteins and their molecular weight in synovial fluid and indicate that thrombin can be generated in synovial fluid. The inactivation of thrombin in synovial fluid may be more dependent on antithrombin-III than in plasma because of the increased AT-III/alpha-2 macroglobulin ratio seen in synovial fluid.

摘要

作为血管外凝血的一个模型,对骨关节炎患者滑液的凝血剂含量和凝血酶生成潜力进行了研究。单个凝血蛋白的浓度与它们的分子量部分相关。非常大的凝血因子V、因子VIII和血管性血友病因子抗原(vWF:ag)的水平低于正常混合参考血浆中发现的活性的1%,而较小的凝血因子,包括因子IX、XI和凝血酶原,范围在9%至30%之间。滑液中的蛋白酶抑制剂抗凝血酶III(AT-III)和α-2巨球蛋白的水平分别为血浆水平的74%和13%,基于它们的分子量,该水平高于预期。凝血酶原被组织凝血活酶激活的速度比被活化部分凝血活酶时间(aPTT)试剂激活的速度更快。滑液中形成的凝血酶活性比在稀释血浆中形成的凝血酶活性下降得更快。向滑液中添加重组因子VIII或牛因子V可通过APTT加速凝血酶的产生,但不能通过组织凝血活酶加速。这表明因子VIII和因子V的低水平确实限制了凝血酶的产生速度。向因子VIII或因子V添加特异性抗体可强烈抑制aPTT产生凝血酶。这些数据证实了滑液中凝血蛋白浓度与其分子量之间大致呈反比关系,并表明滑液中可产生凝血酶。由于滑液中AT-III/α-2巨球蛋白比例增加,滑液中凝血酶的失活可能比血浆中更依赖抗凝血酶III。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验